Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 3 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 6 | 1 |
| Herpes Market to 2018 - Introduction | 7 | 1 |
| GBI Research Report Guidance | 7 | 1 |
| Herpes Market to 2018 - Market Overview | 8 | 6 |
| Introduction to Herpes Virus | 8 | 1 |
| Types of Herpes Virus | 8 | 1 |
| Herpes Simplex Infections | 8 | 1 |
| Herpes Zoster Infections | 8 | 1 |
| Cytomegalovirus Infections | 9 | 1 |
| Congenital CMV Infections | 9 | 1 |
| CMV Infection in Transplant Recipients | 9 | 1 |
| CMV Retinitis in AIDS Patients | 9 | 1 |
| Introduction to Herpes Market | 10 | 1 |
| Revenue | 10 | 1 |
| Annual Cost of Treatment ($) | 11 | 1 |
| Treatment Usage Pattern | 12 | 1 |
| Diseased Population | 13 | 1 |
| Treatment Seeking Population | 13 | 1 |
| Diagnosed Population | 13 | 1 |
| Prescription Population | 13 | 1 |
| Herpes Market to 2018 - Geographical Landscape | 14 | 13 |
| Geographical Segmentation | 14 | 2 |
| The US | 16 | 1 |
| Revenue | 16 | 1 |
| Treatment Usage Pattern | 17 | 1 |
| Diseased Population | 18 | 1 |
| Treatment Seeking Population | 18 | 1 |
| Diagnosed Population | 18 | 1 |
| Prescription Population | 18 | 1 |
| Top Five Countries of Europe | 19 | 1 |
| Revenue | 19 | 3 |
| Treatment Usage Pattern | 22 | 1 |
| Diseased Population | 23 | 1 |
| Treatment Seeking Population | 23 | 1 |
| Diagnosed Population | 23 | 1 |
| Prescription Population | 23 | 1 |
| Japan | 24 | 1 |
| Revenue | 24 | 1 |
| Treatment Usage Pattern | 25 | 1 |
| Diseased Population | 26 | 1 |
| Treatment Seeking Population | 26 | 1 |
| Diagnosed Population | 26 | 1 |
| Prescription Population | 26 | 1 |
| Herpes Market to 2018 - Therapeutic Landscape | 27 | 19 |
| Global Herpes Therapeutics Market | 27 | 1 |
| Introduction Herpes Simplex Infection | 27 | 1 |
| Genital Herpes | 27 | 1 |
| Herpes Labialis | 27 | 1 |
| Treatment of Herpes Simplex Infections | 27 | 1 |
| Introduction to Herpes Zoster Infection | 28 | 1 |
| Treatment of Herpes Zoster Infections | 29 | 1 |
| Revenue | 29 | 1 |
| Revenue by Country | 30 | 2 |
| Branded vs Generics | 32 | 1 |
| Annual Cost of Treatment | 33 | 1 |
| Treatment Usage Pattern | 34 | 1 |
| Diseased Population | 35 | 1 |
| Treatment Seeking Population | 35 | 1 |
| Diagnosed Population | 35 | 1 |
| Prescription Population | 36 | 1 |
| Drivers and Restraints for the Herpes Therapeutics Market | 36 | 1 |
| Drivers and Restraints for the Herpes Simplex Market | 36 | 1 |
| Drivers | 36 | 1 |
| Restraints | 37 | 1 |
| Global Cytomegalovirus Therapeutics Market | 37 | 1 |
| Introduction | 37 | 1 |
| Congenital CMV Infection | 37 | 1 |
| CMV Infections in Transplant Recipients | 37 | 1 |
| CMV Infections in HIV/AIDS patients | 37 | 1 |
| Revenue | 38 | 1 |
| Revenue by Country | 39 | 2 |
| Branded-Generic Share | 41 | 1 |
| Annual Cost of Treatment | 42 | 1 |
| Treatment Usage Pattern | 43 | 1 |
| Diseased Population | 44 | 1 |
| Treatment Seeking Population | 44 | 1 |
| Diagnosed Population | 44 | 1 |
| Prescription Population | 44 | 1 |
| Drivers and Restraints for the CMV Infections Market | 45 | 1 |
| Drivers | 45 | 1 |
| Restraints | 45 | 1 |
| Herpes Market to 2018 - Pipeline Analysis | 46 | 11 |
| Introduction | 46 | 1 |
| Research and Development Pipeline by Indication | 46 | 6 |
| Profiles of Promising Molecules in the Herpes Therapeutics Market | 52 | 1 |
| BA-021 | 52 | 1 |
| Introduction | 52 | 1 |
| Mechanism of Action | 52 | 1 |
| Clinical Development | 52 | 1 |
| NB-001 | 52 | 1 |
| Introduction | 52 | 1 |
| Mechanism of Action | 52 | 1 |
| Clinical Development | 53 | 1 |
| ARYS-01 | 54 | 1 |
| Introduction | 54 | 1 |
| Mechanism of Action | 54 | 1 |
| Clinical Development | 54 | 1 |
| GSK 1437173A | 54 | 1 |
| Introduction | 54 | 1 |
| Mechanism of Action | 54 | 1 |
| Clinical Development | 55 | 1 |
| V212 | 55 | 1 |
| Introduction | 55 | 1 |
| Mechanism of Action | 55 | 1 |
| Clinical Development | 55 | 1 |
| TransVax | 55 | 1 |
| Introduction | 55 | 1 |
| Mechanism of Action | 55 | 1 |
| Clinical Development | 56 | 1 |
| Adoptive Cellular Therapy (CMV Specific T-Cells) | 56 | 1 |
| Introduction | 56 | 1 |
| Mechanism of action | 56 | 1 |
| Clinical Development | 56 | 1 |
| Herpes Market to 2018 - Competitive Landscape | 57 | 5 |
| Competitive Profiling | 57 | 1 |
| GlaxoSmithKline | 57 | 1 |
| Company Overview | 57 | 1 |
| Product Portfolio | 57 | 1 |
| SWOT | 58 | 1 |
| Novartis AG | 58 | 1 |
| Company Overview | 58 | 1 |
| Product Portfolio | 58 | 1 |
| SWOT | 59 | 1 |
| Merck | 59 | 1 |
| Company Overview | 59 | 1 |
| Product Portfolio | 59 | 1 |
| SWOT | 60 | 1 |
| Roche | 60 | 1 |
| Company Overview | 60 | 1 |
| Product Portfolio | 60 | 1 |
| SWOT | 61 | 1 |
| Herpes Market to 2018 - Strategic Consolidations | 62 | 4 |
| Overview | 62 | 1 |
| Deals by Type of Agreement | 62 | 1 |
| Deals by Year | 63 | 1 |
| Deals by Geography | 64 | 1 |
| Profiling of Major Deals, 2007-2011 | 65 | 1 |
| VBI Vaccines Acquires Epixis | 65 | 1 |
| Meda Amends Licensing Agreement with Medivir | 65 | 1 |
| Centaur Pharmaceuticals Enters into Licensing Agreement With aRigen Pharmaceuticals | 65 | 1 |
| GlaxoSmithKline Enters Into Licensing Agreement with Medivir | 65 | 1 |
| GlaxoSmithKline Enters Into Licensing Agreement with NanoBio | 65 | 1 |
| Novartis Enters Into Licensing Agreement with AlphaVax | 65 | 1 |
| Herpes Market to 2018 - Appendix | 66 | 7 |
| Market Definitions | 66 | 1 |
| Abbreviations | 66 | 1 |
| Research Methodology | 66 | 6 |
| Coverage | 67 | 1 |
| Secondary Research | 67 | 1 |
| Primary Research | 67 | 1 |
| Therapeutic Landscape | 68 | 1 |
| Epidemiology-based Forecasting | 68 | 2 |
| Market Size by Geography | 70 | 1 |
| Geographical Landscape | 71 | 1 |
| Pipeline Analysis | 71 | 1 |
| Competitive Landscape | 71 | 1 |
| Expert Panel Validation | 71 | 1 |
| Contact Us | 71 | 1 |
| Disclaimer | 71 | 1 |
| Sources | 72 | 1 |